Current clinical evidence for nucleos(t)ide analogues in patients with HBV-related hepatocellular carcinoma

References

• Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin. 2012;62:394–399.
   PubMed Web of Science ®Google Scholar
• Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529–538.
   PubMed Web of Science ®Google Scholar
• El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264–1273.
   PubMed Web of Science ®Google Scholar
• Yu MW, Yeh SH, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst. 2005;97:265–272.
   PubMed Web of Science ®Google Scholar
• Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. Jama. 2006;295:65–73.
   PubMed Web of Science ®Google Scholar
• Hung IF, Poon RT, Lai CL, et al. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol. 2008;103:1663–1673.
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ, Brown RS, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. Hepatology. 2016 Jan;63(1):284–306.
   PubMed Web of Science ®Google Scholar
• Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521–1531.
   PubMed Web of Science ®Google Scholar
• Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013;58:98–107.
   PubMed Web of Science ®Google Scholar
• Kim WR, Loomba R, Berg T, et al. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Cancer. 2015;121:3631–3638.
   PubMed Web of Science ®Google Scholar
• Liu GM, Huang XY, Shen SL, et al. Adjuvant antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after curative treatment: A systematic review and meta-analysis. Hepatol Res. 2016;46:100–110.
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–185.
   PubMed Web of Science ®Google Scholar
• Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98.
   PubMed Web of Science ®Google Scholar
• Ayoub WS, Keeffe EB. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther. 2011;34:1145–1158.
   PubMed Web of Science ®Google Scholar
• Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001–1010.
   PubMed Web of Science ®Google Scholar
• Marcellin P, Buti M, Krastev Z, et al. Continued efficacy and safety through 4 years of tenofovir disoproxil fumarate (TDF) treatment in HBeAg negative patients with chronic hepatitis B (study 102): preliminary analysis. Hepatology. 2010;52(4 Suppl.):555A.
   Web of Science ®Google Scholar
• Heathcote EJ, Gane EJ, De Man R, et al. Long term (4 years) efficacy and safety of tenofovir disoproxil fumarate (TDF) treatment in HBeAG-positive patients (HBeAg+) with chronic hepatitis B (Study 103): preliminary analysis. Hepatology. 2010;52(4 Suppl.):556A.
   Web of Science ®Google Scholar
• Terrault NA, Bzowej NH, Chang KM, et al. American association for the study of liver diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–283.
   PubMed Web of Science ®Google Scholar
• Wu CY, Lin JT, Ho HJ, et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology. 2014;147:143–151, e145.
   PubMed Web of Science ®Google Scholar
• Murray KF, Carithers RL Jr, Aasld. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology. 2005;41:1407–1432.
   PubMed Web of Science ®Google Scholar
• Papatheodoridis GV, Cholongitas E, Archimandritis AJ, et al. Current management of hepatitis B virus infection before and after liver transplantation. Liver Int. 2009;29:1294–1305.
   PubMed Web of Science ®Google Scholar
• Papatheodoridis GV, Sevastianos V, Burroughs AK. Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era. Am J Transplant. 2003;3:250–258.
   PubMed Web of Science ®Google Scholar
• Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl. 2007;13:349–360.
   PubMed Web of Science ®Google Scholar
• Hou J, Yin YK, Xu D, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology. 2008;47:447–454.
   PubMed Web of Science ®Google Scholar
• Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007;357:2576–2588.
   PubMed Web of Science ®Google Scholar
• Chan HL, Chen YC, Gane EJ, et al. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related decompensated cirrhosis. J Viral Hepat. 2012;19:732–743.
   PubMed Web of Science ®Google Scholar
• Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354:1011–1020.
   PubMed Web of Science ®Google Scholar
• Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology. 2006;130:2039–2049.
   PubMed Web of Science ®Google Scholar
• Manolakopoulos S, Karatapanis S, Elefsiniotis J, et al. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection. Am J Gastroenterol. 2004;99:57–63.
   PubMed Web of Science ®Google Scholar
• Perrillo RP, Wright T, Rakela J, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology. 2001;33:424–432.
   PubMed Web of Science ®Google Scholar
• Fontana RJ, Keeffe EB, Carey W, et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl. 2002;8:433–439.
   PubMed Web of Science ®Google Scholar
• Lake JR. Do we really need long-term hepatitis B hyperimmune globulin? What are the alternatives? Liver Transpl. 2008;14(Suppl 2):S23–26.
   PubMed Web of Science ®Google Scholar
• Gilson RJ, Chopra KB, Newell AM, et al. A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. J Viral Hepat. 1999;6:387–395.
   PubMed Web of Science ®Google Scholar
• Sonneveld MJ, Janssen HL. Chronic hepatitis B: peginterferon or nucleos(t)ide analogues? Liver Int. 2011;31(Suppl 1):78–84.
   PubMed Web of Science ®Google Scholar
• Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886–893.
   PubMed Web of Science ®Google Scholar
• Lim YS, Han S, Heo NY, et al. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine. Gastroenterology. 2014;147:152–161.
   PubMed Web of Science ®Google Scholar
• Jang JW, Choi JY, Kim YS, et al. Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis. Hepatology. 2015;61:1809–1820.
   PubMed Web of Science ®Google Scholar
• Tenny DJ, Pokornowski KA, Rose RE, et al. Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance. Zeitschrift Fur Gastroenterologie. 2008;46(9). DOI: 10.1055/s-0028-1089435.
   Google Scholar
• Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468–475.
   PubMed Web of Science ®Google Scholar
• Miquel M, Nunez O, Trapero-Marugan M, et al. Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice. Ann Hepatol. 2013;12:205–212.
   PubMed Web of Science ®Google Scholar
• Hung CH, Hu TH, Lu SN, et al. Tenofovir versus entecavir in treatment of chronic hepatitis B virus with severe acute exacerbation. Antimicrob Agents Chemother. 2015;59:3168–3173.
   PubMed Web of Science ®Google Scholar
• Wang ZX, Fu ZR, Ding GS, et al. Prevention of hepatitis B virus reinfection after orthotopic liver transplantation. Transplant Proc. 2004;36:2315–2317.
   PubMed Web of Science ®Google Scholar
• Ahn J, Cohen SM. Prevention of hepatitis B recurrence in liver transplant patients using oral antiviral therapy without long-term hepatitis B immunoglobulin. Hepat Mon. 2011;11:638–645.
   PubMed Web of Science ®Google Scholar
• Fung J, Cheung C, Chan SC, et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology. 2011;141:1212–1219.
   PubMed Web of Science ®Google Scholar
• Cholongitas E, Vasiliadis T, Antoniadis N, et al. Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation. Transpl Infect Dis. 2012;14:479–487.
   PubMed Web of Science ®Google Scholar
• Perrillo R, Buti M, Durand F, et al. Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B. Liver Transpl. 2013;19(8):887–895.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Renner EL, Selzner N, et al. One year of hepatitis B immunoglobulin plus tenofovir therapy is safe and effective in preventing recurrent hepatitis B infection post-liver transplantation. Can J Gastroenterol Hepatol. 2014;28(1):41–44.
   PubMed Web of Science ®Google Scholar
• Ueda Y, Marusawa H, Kaido T, et al. Efficacy and safety of prophylaxis with entecavir and hepatitis B immunoglobulin in preventing hepatitis B recurrence after living-donor liver transplantation. Hepatol Res. 2013;43(1):67–71.
   PubMed Web of Science ®Google Scholar
• Gao YJ, Zhang M, Jin B, et al. A clinicalpathological analysis of hepatitis B virus recurrence after liver transplantation in Chinese patients. J Gastroenterol Hepatol. 2014;29(3):554–560.
   PubMed Web of Science ®Google Scholar
• Kim YK, Kim SH, Lee SD, et al. Clinical outcomes and risk factors of hepatitis B virus recurrence in patients who received prophylaxis with entecavir and hepatitis B immunoglobulin following liver transplantation. Transplant Proc. 2013;45(8):3052–3056.
   PubMed Web of Science ®Google Scholar
• Lee S, Kwon CH, Moon HH, et al. Antiviral treatment for hepatitis B virus recurrence following liver transplantation. Clin Transplant. 2013;27(5):E597–604.
   PubMed Web of Science ®Google Scholar
• Malkan G, Cattral MS, Humar A, et al. Lamivudine for hepatitis B in liver transplantation: a single-center experience. Transplantation. 2000;69:1403–1407.
   PubMed Web of Science ®Google Scholar
• Mutimer D, Dusheiko G, Barrett C, et al. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up. Transplantation. 2000;70:809–815.
   PubMed Web of Science ®Google Scholar
• Mutimer D, Pillay D, Shields P, et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut. 2000;46:107–113.
   PubMed Web of Science ®Google Scholar
• Chan HL, Chui AK, Lau WY, et al. Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprophylaxis. Clin Transplant. 2004;18:295–300.
   PubMed Web of Science ®Google Scholar
• Jimenez-Perez M, Gonzalez-Grande R, Mostazo Torres J, et al. Management of hepatitis B virus infection after liver transplantation. World J Gastroenterol. 2015;21:12083–12090.
   PubMed Web of Science ®Google Scholar
• Jiang L, Yan L, Wen T, et al. Hepatitis B prophylaxis using lamivudine and individualized low-dose hepatitis B immunoglobulin in living donor liver transplantation. Transplant Proc. 2013;45:2326–2330.
   PubMed Web of Science ®Google Scholar
• Loomba R, Rowley AK, Wesley R, et al. Hepatitis B immunoglobulin and Lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis. Clin Gastroenterol Hepatol. 2008;6:696–700.
   PubMed Web of Science ®Google Scholar
• Cholongitas E, Papatheodoridis GV. High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review. Am J Transplant. 2013;13:353–362.
   PubMed Web of Science ®Google Scholar
• Nath DS, Kalis A, Nelson S, et al. Hepatitis B prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin therapy. Clin Transplant. 2006;20:206–210.
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. American association for the study of liver diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–1022.
   PubMed Web of Science ®Google Scholar
• Pawlik TM, Poon RT, Abdalla EK, et al. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery. 2005;137:403–410.
   PubMed Web of Science ®Google Scholar
• Chau GY. Resection of hepatitis B virus-related hepatocellular carcinoma: evolving strategies and emerging therapies to improve outcome. World J Gastroenterol. 2014;20:12473–12484.
   PubMed Web of Science ®Google Scholar
• Lin S, Hoffmann K, Schemmer P. Treatment of hepatocellular carcinoma: a systematic review. Liver Cancer. 2012;1:144–158.
   PubMed Web of Science ®Google Scholar
• Ke Y, Ma L, You XM, et al. Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy. Cancer Biol Med. 2013;10:158–164.
   PubMedGoogle Scholar
• Guglielmi A, Ruzzenente A, Conci S, et al. Hepatocellular carcinoma: surgical perspectives beyond the barcelona clinic liver cancer recommendations. World J Gastroenterol. 2014;20:7525–7533.
   PubMed Web of Science ®Google Scholar
• Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200–207.
   PubMed Web of Science ®Google Scholar
• Ho CM, Lee PH, Shau WY, et al. Survival in patients with recurrent hepatocellular carcinoma after primary hepatectomy: comparative effectiveness of treatment modalities. Surgery. 2012;151:700–709.
   PubMed Web of Science ®Google Scholar
• Wu JC, Huang YH, Chau GY, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol. 2009;51:890–897.
   PubMed Web of Science ®Google Scholar
• Kuzuya T, Katano Y, Kumada T, et al. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol Hepatol. 2007;22:1929–1935.
   PubMed Web of Science ®Google Scholar
• Someya T, Ikeda K, Saitoh S, et al. Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis. J Gastroenterol. 2006;41:1206–1213.
   PubMed Web of Science ®Google Scholar
• Chan AC, Chok KS, Yuen WK, et al. Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma. Arch Surg. 2011;146:675–681.
   PubMed Web of Science ®Google Scholar
• Wu CY, Chen YJ, Ho HJ, et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. Jama. 2012;308:1906–1914.
   PubMed Web of Science ®Google Scholar
• Lee TY, Lin JT, Zeng YS, et al. Association between nucleos(t)ide analogue and tumor recurrence in HBV-related hepatocellular carcinoma after radiofrequency ablation. Hepatology. 2016;63(5):1517–1527.
   PubMed Web of Science ®Google Scholar
• Hann HW, Coben R, Brown D, et al. A long-term study of the effects of antiviral therapy on survival of patients with HBV-associated hepatocellular carcinoma (HCC) following local tumor ablation. Cancer Med. 2014;3:390–396.
   PubMed Web of Science ®Google Scholar
• Piao CY, Fujioka S, Iwasaki Y, et al. Lamivudine treatment in patients with HBV-related hepatocellular carcinoma–using an untreated, matched control cohort. Acta Med Okayama. 2005;59:217–224.
   PubMed Web of Science ®Google Scholar
• Kim BK, Park JY, Kim DY, et al. Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver Int. 2008;28:393–401.
   PubMed Web of Science ®Google Scholar
• Miao RY, Zhao HT, Yang HY, et al. Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis. World J Gastroenterol. 2010;16:2931–2942.
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan PK, Hui P, et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol. 2003;70:553–561.
   PubMed Web of Science ®Google Scholar
• Jang JW. Hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy. World J Gastroenterol. 2014;20:7675–7685.
   PubMed Web of Science ®Google Scholar
• Xunrong L, Yan AW, Liang R, et al. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy–pathogenesis and management. Rev Med Virol. 2001;11:287–299.
   PubMed Web of Science ®Google Scholar
• Chung YL, Tsai TY. Promyelocytic leukemia nuclear bodies link the DNA damage repair pathway with hepatitis B virus replication: implications for hepatitis B virus exacerbation during chemotherapy and radiotherapy. Mol Cancer Res. 2009;7:1672–1685.
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Ouyang DL, Keeffe EB. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther. 2006;24:1003–1016.
   PubMed Web of Science ®Google Scholar
• Hsu C, Hsiung CA, Su IJ, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin’s lymphoma: a randomized trial. Hepatology. 2008;47:844–853.
   PubMed Web of Science ®Google Scholar
• Yun J, Kim KH, Kang ES, et al. Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy. Br J Cancer. 2011;104:559–563.
   PubMed Web of Science ®Google Scholar
• Hui CK, Cheung WW, Au WY, et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut. 2005;54:1597–1603.
   PubMed Web of Science ®Google Scholar
• Saab S, Dong MH, Joseph TA, et al. Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision analysis model. Hepatology. 2007;46:1049–1056.
   PubMed Web of Science ®Google Scholar
• Cortelezzi A, Vigano M, Zilioli VR, et al. Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H. J Clin Virol. 2006;35:467–469.
   PubMed Web of Science ®Google Scholar
• Pelizzari AM, Motta M, Cariani E, et al. Frequency of hepatitis B virus mutant in asymptomatic hepatitis B virus carriers receiving prophylactic lamivudine during chemotherapy for hematologic malignancies. Hematol J. 2004;5:325–328.
   PubMedGoogle Scholar
• Li HR, Huang JJ, Guo HQ, et al. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. J Viral Hepat. 2011;18:877–883.
   PubMed Web of Science ®Google Scholar
• Li X, Zhong X, Chen ZH, et al. Efficacy of prophylactic entecavir for hepatitis B virus-related hepatocellular carcinoma receiving transcatheter arterial chemoembolization. Asian Pac J Cancer Prev. 2015;16:8665–8670.
   PubMedGoogle Scholar
• Ye XG, Su QM. Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: meta-analysis. World J Gastroenterol. 2013;19:6665–6678.
   PubMed Web of Science ®Google Scholar
• Jiang E, Shangguan AJ, Chen S, et al. The progress and prospects of routine prophylactic antiviral treatment in hepatitis B-related hepatocellular carcinoma. Cancer Lett. 2015;379(2):262–267.
   PubMed Web of Science ®Google Scholar
• Fung J, Lai CL, Yuen MF. Management of chronic hepatitis B in severe liver disease. World J Gastroenterol. 2014;20:16053–16061.
   PubMed Web of Science ®Google Scholar
• Kayaaslan B, Guner R. Adverse effects of oral antiviral therapy in chronic hepatitis B. World J Hepatol. 2017;9:227–241.
   PubMed Web of Science ®Google Scholar
• Zeisel MB, Lucifora J, Mason WS, et al. Towards an HBV cure: state-of-the-art and unresolved questions–report of the ANRS workshop on HBV cure. Gut. 2015;64:1314–1326.
   PubMed Web of Science ®Google Scholar
• Nguyen VTT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat. 2009;16(7):453–463.
   PubMed Web of Science ®Google Scholar
• Lee HW, Ahn SH. Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients. World J Gastroenterol. 2016;22(37):8314–8321.
   PubMed Web of Science ®Google Scholar